Oncology Central

NICE rejects Kymriah® for adults with lymphoma

NICE have issued draft guidance concluding that Novartis’ (Basel, Switzerland) CAR-T cell therapy Kymriah® (tisagenlecleucel) is too expensive to recommend as a treatment for certain adults with lymphoma.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.